Smith IE - Search Results

1

Clinical and endocrine effects of leuprorelin acetate in pre- and postmenopausal patients with advanced breast cancer.

Dowsett M, Jacobs S, Aherne J, Smith IE. Dowsett M, et al. Among authors: smith ie. Clin Ther. 1992;14 Suppl A:97-103. Clin Ther. 1992. PMID: 1606596 Clinical Trial.

2

An endocrine and pharmacokinetic study of four oral doses of formestane in postmenopausal breast cancer patients.

Dowsett M, Mehta A, King N, Smith IE, Powles TJ, Stein RC, Coombes RC. Dowsett M, et al. Among authors: smith ie. Eur J Cancer. 1992;28(2-3):415-20. doi: 10.1016/s0959-8049(05)80065-6. Eur J Cancer. 1992. PMID: 1591054 Clinical Trial.

3

A dose-comparative endocrine-clinical study of leuprorelin in premenopausal breast cancer patients.

Dowsett M, Mehta A, Mansi J, Smith IE. Dowsett M, et al. Among authors: smith ie. Br J Cancer. 1990 Nov;62(5):834-7. doi: 10.1038/bjc.1990.388. Br J Cancer. 1990. PMID: 2123115 Free PMC article. Clinical Trial.

4

Use of luteinising hormone-releasing hormone agonist (leuprorelin) in advanced post-menopausal breast cancer: clinical and endocrine effects.

Crighton IL, Dowsett M, Lal A, Man A, Smith IE. Crighton IL, et al. Among authors: smith ie. Br J Cancer. 1989 Oct;60(4):644-8. doi: 10.1038/bjc.1989.331. Br J Cancer. 1989. PMID: 2508735 Free PMC article.

5

Clinical and endocrine effects of the oral aromatase inhibitor vorozole in postmenopausal patients with advanced breast cancer.

Johnston SR, Smith IE, Doody D, Jacobs S, Robertshaw H, Dowsett M. Johnston SR, et al. Among authors: smith ie. Cancer Res. 1994 Nov 15;54(22):5875-81. Cancer Res. 1994. PMID: 7954417 Clinical Trial.

6

Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer.

Iveson TJ, Smith IE, Ahern J, Smithers DA, Trunet PF, Dowsett M. Iveson TJ, et al. Among authors: smith ie. Cancer Res. 1993 Jan 15;53(2):266-70. Cancer Res. 1993. PMID: 8417819 Clinical Trial.

7

In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer.

Dowsett M, Jones A, Johnston SR, Jacobs S, Trunet P, Smith IE. Dowsett M, et al. Among authors: smith ie. Clin Cancer Res. 1995 Dec;1(12):1511-5. Clin Cancer Res. 1995. PMID: 9815951 Clinical Trial.

8

Towards a molecular basis for tamoxifen resistance in breast cancer.

Johnston SR, Dowsett M, Smith IE. Johnston SR, et al. Among authors: smith ie. Ann Oncol. 1992 Jul;3(7):503-11. doi: 10.1093/oxfordjournals.annonc.a058251. Ann Oncol. 1992. PMID: 1498070 Free article. Review.

9

A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients.

Dowsett M, Harris AL, Stuart-Harris R, Hill M, Cantwell BM, Smith IE, Jeffcoate SL. Dowsett M, et al. Among authors: smith ie. Br J Cancer. 1985 Oct;52(4):525-9. doi: 10.1038/bjc.1985.223. Br J Cancer. 1985. PMID: 2933050 Free PMC article.

10

The effects of low and high dose medroxyprogesterone acetate on sex steroids and sex hormone binding globulin in postmenopausal breast cancer patients.

Dowsett M, Lal A, Smith IE, Jeffcoate SL. Dowsett M, et al. Among authors: smith ie. Br J Cancer. 1987 Mar;55(3):311-3. doi: 10.1038/bjc.1987.61. Br J Cancer. 1987. PMID: 2952154 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

518 results

Search Page

Filters